Distinct renal adverse event profiles among CDK4/6 inhibitors: a comparative pharmacovigilance analysis.

Guzel SS, Alan AM, Tay K, Demirci NS, Alan O

Open source

DOI
10.3389/fphar.2026.1917719
Published
2026
Container
Frontiers in pharmacology
Publisher
Not recorded
Open access
yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3389/fphar.2026.1917719,
  title = {Distinct renal adverse event profiles among CDK4/6 inhibitors: a comparative pharmacovigilance analysis.},
  author = {Guzel SS and Alan AM and Tay K and Demirci NS and Alan O},
  year = {2026},
  journal = {Frontiers in pharmacology},
  doi = {10.3389/fphar.2026.1917719},
  url = {https://doi.org/10.3389/fphar.2026.1917719}
}

RIS

TY  - JOUR
TI  - Distinct renal adverse event profiles among CDK4/6 inhibitors: a comparative pharmacovigilance analysis.
AU  - Guzel SS
AU  - Alan AM
AU  - Tay K
AU  - Demirci NS
AU  - Alan O
PY  - 2026
JO  - Frontiers in pharmacology
DO  - 10.3389/fphar.2026.1917719
UR  - https://doi.org/10.3389/fphar.2026.1917719
ER  - 

APA

SS, G., AM, A., K, T., NS, D., & O, A. (2026). Distinct renal adverse event profiles among CDK4/6 inhibitors: a comparative pharmacovigilance analysis.. Frontiers in pharmacology. https://doi.org/10.3389/fphar.2026.1917719

Source records